昔萘酸沙美特罗(Salmeterol Xinafoate) - 药物靶点：β2-adrenergic receptor_在研适应症：哮喘，慢性阻塞性肺疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(S)-salmeterol、S-salmeterol、SN 408 dry-powder inhalation

+ [23]

靶点

β2-adrenergic receptor

作用方式

激动剂

作用机制

β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Boehringer Ingelheim GmbH

非在研机构

Neothetics, Inc.Evofem, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1994-02-04),

哮喘慢性阻塞性肺疾病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C36H45NO7

InChIKeyXTZNCVSCVHTPAI-UHFFFAOYSA-N

CAS号94749-08-3

查看全部结构式(2)

关联

127

项与昔萘酸沙美特罗相关的临床试验

NCT06654986

/ Not yet recruitingN/A

The Importance of Amino Acid Availability in Modulating the Muscle Anabolic Response to Β2-adrenergic Stimulation.

The purpose of the project is to investigate the effect of amino acid availability on the muscle anabolic response to beta2-adrenergic stimulation in young healthy men and women.

开始日期2024-11-01

申办/合作机构

University of Copenhagen

NCT06655012

/ Not yet recruitingN/A

The Muscle Anabolic Response to Β2-adrenergic Stimulation

The purpose of the project is to investigate the muscle anabolic response to acute beta2-adrenergic stimulation in young healthy men and women.

开始日期2024-11-01

申办/合作机构

University of Copenhagen

NCT05697003

/ Active, not recruiting临床1期

A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder

开始日期2023-02-17

申办/合作机构

润生药业有限公司

[+1]

100 项与昔萘酸沙美特罗相关的临床结果

登录后查看更多信息

100 项与昔萘酸沙美特罗相关的转化医学

登录后查看更多信息

100 项与昔萘酸沙美特罗相关的专利（医药）

登录后查看更多信息

4,117

项与昔萘酸沙美特罗相关的文献（医药）

2025-03-01·Pulmonary Therapy

A Retrospective Study Evaluating Asthma Control in Patients on Fluticasone Propionate/Salmeterol Proactive Regular Dosing with a History of Uncontrolled Asthma

Article

作者: Samsudin, Azlina ; Ban, Andrea Yu-Lin ; Lai, Siew Li ; Wong, Chee Kuan ; Abu Bakar, Zamzurina ; Ismail, Ahmad Izuanuddin ; Alaga, Arvindran ; Gandhi, Alap ; Lem, Li Khen ; Mz Zahrah, Fatimah ; MZ Zahrah, Fatimah ; Omar, Azza ; Hyder Ali, Irfhan Ali

INTRODUCTIONThe MERIT study in Malaysia is a real-world retrospective, observational, multicenter study that evaluated asthma control in patients with uncontrolled asthma who were switched from as-needed (pro re nata [PRN]) budesonide/formoterol or inhaled corticosteroid (ICS) whenever a short-acting beta-agonist (SABA) was taken, to proactive regular dosing of fluticasone propionate/salmeterol (FP/SAL PRD).METHODSData from the medical records of patients who were stepped up to FP/SAL PRD were extracted retrospectively at baseline and follow-up (between 3 and 6 months after stepping up to FP/SAL PRD). The primary endpoint was the percentage of patients with improvement in asthma control assessed via the Asthma Control Test (ACT). Secondary endpoints included safety and the percentage of patients with moderate and severe exacerbations. Additionally, patient-reported use of reliever medication, systemic corticosteroids, emergency department visits, or hospitalization was also analyzed.RESULTSOne hundred twenty patients with uncontrolled asthma who were stepped up to FP/SAL PRD were enrolled in the study. Of these, 76 (63.3%) patients were on prior budesonide/formoterol PRN, and 44 (36.7%) were on prior ICS with SABA PRN treatment. After stepping up to FP/SAL PRD with a mean follow-up of 5.8 months, 110 (91.7%) patients achieved asthma control at the follow-up visit (p < 0.001). Similar improvements were observed regardless of prior PRN regimen. A statistically significant improvement was observed in the mean ACT score at the follow-up visit (p < 0.0001). The proportion of patients with moderate and severe exacerbations was also reduced after stepping up to FP/SAL PRD, with no adverse events reported. Over 80% of patients reported a decrease in the use of systemic corticosteroids, visits to the emergency department, or hospitalization.CONCLUSIONThis study highlights the effectiveness of the FP/SAL PRD treatment approach in patients with uncontrolled asthma on a PRN treatment regimen.

2025-03-01·Clinical & Experimental Ophthalmology

Drug‐associated glaucoma: A real‐world study based on the Food and Drug Administration adverse event reporting system database

Article

作者: Hu, Jiaoyue ; Wu, Shi‐Nan ; Chen, Xiao‐Dong ; Liu, Zuguo ; Yan, Dan ; Wang, Shao‐Pan ; Guan, Wen‐Ying ; Wang, Yu‐Qian ; Huang, Caihong

AbstractBackgroundThis study aims to assess the risk of drug‐associated glaucoma and track its epidemiological characteristics using real‐world data.MethodsAdverse event reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to December 2023 were analysed. Disproportionality analysis and the Bayesian Confidence Propagation Neural Network algorithm were used. The study classified drugs associated with glaucoma, assessed risk levels, and compared drug‐induced times across different categories.ResultsEight hundred and five drugs were linked to glaucoma in the FAERS database. Disproportionality analysis identified 46 drugs with significant risk, mainly adrenergic medications (clobetasol propionate, fluocinolone acetonide), antihypertensives (hydrochlorothiazide), insulin (insulin human), anticholinergics (umeclidinium, darifenacin), VEGF inhibitors (brolucizumab, faricimab), and psychotropics (topiramate, ziprasidone). The top three high‐risk drugs were clobetasol propionate, umeclidinium, and fluocinolone acetonide. The shortest drug‐induced times were observed with indacaterol, salmeterol, and umeclidinium. Anticholinergic medications had the shortest drug‐induced time among all categories. Females (62.5%) and the elderly (average age 63.5 ± 16.8 years) were predominantly affected. Reports of drug‐associated glaucoma increased over the years.ConclusionPreventing drug‐associated glaucoma is more effective than treatment. Identifying the risk and drug‐induced times of systemic and ophthalmic drugs can reduce occurrence risk. Clinical practitioners should be vigilant and inform patients of these risks.

2025-02-01·Chromatographia

Development and Validation of Confirmatory Quantitative and Screening Methods for 63 Prohibited Substances in Horse Urine Using LC–MS/MS

作者: Goktas, Eylem Funda ; Kabil, Erol

Abstract: The number of potentially abused substances in horse racing is very large and it is not easy to analyze the full range.To facilitate the analyses of substances of abuse, a method has been developed for 63 substances in horse urine using liquid chromatog.-tandem mass spectrometry.The developed method has been validated according to the 2021/808/EC and AORC criteria.The horse urine samples were extracted after enzymic hydrolysis via a C8-BCX SPE cartridge with an automated SPE and analyzed by LC-MS/MS.According to the validation study results, the within-laboratory reproducibility CV was no more than 13.9% and the average recoveries ranged from 90.71 to 117.94% for repeatability and reproducibility.The decision limits (CCα) for quant. anal. and detection capabilities (CCβ) for qual. screening were close to the targeted limit for each substance.The results of the present study showed that the method was able to perform quant. analyses of 54 substances and screening analyses of 9 substances (total 63) in horse urine and that the results were valid and applicable.The validated method was successfully applied to five proficiency tests and three suspected samples.

46

项与昔萘酸沙美特罗相关的新闻（医药）

2025-03-11

·米内网

【瞩目】四川药企拿下17亿高端吸入剂

精彩内容近日，国家药监局官网显示，四川普锐特药业（倍特药业子公司）申报的4类仿制药沙美特罗替卡松吸入粉雾剂获批生产并视同过评，为国产第2家获批，原研产品2023年在中国三大终端六大市场（统计范围详见本文末）的销售额超过17亿元。沙美特罗替卡松吸入粉雾剂是由沙美特罗（长效β2受体激动剂）和丙酸氟替卡松（吸入性糖皮质激素）组成的复方制剂，适用于可逆性气道阻塞性气道疾病的规律治疗，包括成人和儿童哮喘等。米内网数据显示，沙美特罗替卡松吸入粉雾剂已被纳入国家医保乙类目录，2023年在中国三大终端六大市场的销售额超过17亿元，2024上半年超过9亿元，在化药吸入剂品牌排名中，葛兰素史克的沙美特罗替卡松吸入粉雾剂排位第三。近年来中国三大终端六大市场沙美特罗替卡松吸入粉雾剂销售情况（单位：万元）来源：米内网格局数据库目前国内有10余家企业布局沙美特罗替卡松吸入粉雾剂仿制药，其中健康元药业的产品经过多次申报，最终于2024年6月获批生产，拿下国内首仿+首家过评；杭州京瑞医药、四川普锐特药业的产品紧接在后，陆续获批。此外，欧米尼、西普拉、润生药业、Celon等企业的产品报产在审。作为药械合一的特殊制剂产品，吸入剂的研发门槛较高。目前倍特药业已拥有11款吸入剂的生产批文，包括吸入用布地奈德混悬液、吸入用硫酸沙丁胺醇溶液、吸入用异丙托溴铵溶液、盐酸左沙丁胺醇雾化吸入溶液等畅销品种。此外，8个吸入剂以新注册分类申报在审，咪达唑仑鼻喷雾剂、布地奈德福莫特罗吸入气雾剂、糠酸莫米松富马酸福莫特罗吸入气雾剂、丙酸氟替卡松吸入气雾剂等在国内均暂无仿制药获批。倍特药业以新注册分类申报的吸入剂来源：米内网中国申报进度（MED）数据库吸入剂新药方面，3月7日，四川普锐特药业的1类新药PRT-064040鼻喷雾剂提交IND获受理。此前，公司已有3款吸入剂新药处于获批临床及以上阶段，其中1类新药吸入用XQ-001、2类改良型新药盐酸右氯胺酮鼻喷雾剂已步入I期临床。资料来源：米内网数据库、国家药监局官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至3月11日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

临床申请上市批准

2025-03-10

·摩熵医药

6亿高端吸入制剂，四川药企拿下国产第2家！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 3月10日，据NMPA官网最新显示，四川普锐特药业提交的4类仿制药沙美特罗替卡松吸入粉雾剂获批并视同通过一致性评价，成为该产品国产第2家过评的药企。截图来源：NMPA 沙美特罗替卡松吸入粉雾剂原研来自葛兰素史克（GSK）公司的舒利迭，为全球首款支气管扩张剂和皮质激素联用复方吸入制剂，是沙美特罗与丙酸氟替卡松的复方吸入粉雾剂，上市后快速成为治疗哮喘与慢性阻塞性肺疾病的重要产品。舒利迭于2001年在我国首次批准进口，为国家医保乙类药品。据摩熵医药数据库显示，沙美特罗替卡松吸入粉雾剂在2024年（Q1~Q3）全国院内市场销售额近6亿元，是吸入剂TOP7产品。截图来源：摩熵医药全国医院销售数据库此前，沙美特罗替卡松吸入粉雾剂有2家药企拥有生产批文，健康元拿下该品种国内首仿。四川普锐特药业是继健康元之后的第2家获批并过评的药企。截图来源：摩熵医药过评药品汇总数据库长期以来，国内吸入制剂市场的大部分份额一直被进口厂商所垄断。吸入制剂的治疗效果不仅取决于药物本身，还与吸入装置等关键因素紧密相关。粉雾制剂因其技术挑战性较高而显得尤为复杂，其中，药物颗粒在混合物中的物理状态起着至关重要的作用。混合过程需确保所形成的粉雾体系能在较长时间内稳定重现相同的雾化效果。目前，针对高难度且具有技术壁垒的沙美特罗替卡松吸入粉雾剂，国内还有上海欧米尼医药、润生药业等企业提交4类上市仿制申请。截图来源：摩熵医药中国药品审评数据库截至目前，四川普锐特药业布地奈德鼻喷雾剂、吸入用乙酰半胱氨酸溶液、吸入用复方异丙托溴铵溶液等10款品种过评，其中9款品种为吸入剂。此外，布地奈德鼻喷雾剂是该药企独家过评的品种。 END 本文为原创文章，转载请留言获取授权近期热门资源获取 CGT产业现状与未来趋势蓝皮书-202406 中药行业现状与未来趋势白皮书-202407 2023年医药企业综合实力排行榜-202408 跨越国界，引领创新：中国药企出海的布局实践-202408 专利即将到期五大重磅小分子药品，国内仿制药“战况”几何?-202409 中国放射性药物市场现状分析报告-202410 合成生物产业发展前景及中国合成生物产业链上中下游企业分析-202410 中国合成生物学创投市场分析报告-202410 中国糖尿病临床诊疗与药物多渠道市场数据分析-202411 基于剂型改良的复杂注射剂分析--微球篇-202411 2024医美注射材料市场发展分析报告-20241213 国家药品集采跟踪报告-前9批次集采回顾与展望-202411 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

一致性评价医药出海

2025-03-10

·Pharma CMC

吸入剂大爆发！4品规新获批！「沙美特罗替卡松吸入粉雾剂」迎来国产第二家

在今日NMPA发布的批件中，3款吸入剂（4品规）获批上市，分别为：仁合益康的2品规盐酸丙卡特罗吸入溶液；四川普锐特药业的沙美特罗替卡松吸入粉雾剂；山西德元堂药业的吸入用乙酰半胱氨酸溶液。欢迎加入群聊其中，四川普锐特药业的沙美特罗替卡松吸入粉雾剂为国产第二家获批！这里重点提下沙美特罗替卡松吸入粉雾剂，沙美特罗为长效β2受体激动剂，可持久舒张支气管，主要用于用于可逆性气道阻塞性气道疾病的规律治疗，包括成人和儿童哮喘。长期以来，国内绝大部分的吸入制剂市场份额被进口厂家所占据，吸入制剂的医疗效果不仅依赖药物本身，还与吸入装置等因素息息相关。粉雾制剂的技术难度较大，药物颗粒在混合物中的物理状态非常重要，混合过程要求形成的粉雾体系能在相当长的时期内多次重现相同雾化过程。沙美特罗替卡松吸入粉雾剂原研品种为葛兰素史克（GSK）的舒利迭，为全球首款支气管扩张剂和皮质激素联用复方吸入制剂，上市后快速成为治疗哮喘与慢性阻塞性肺疾病的重要产品。舒利迭于2001年在我国首次批准进口，为国家医保乙类药品。 2024年6月，健康元的沙美特罗替卡松吸入粉雾剂获批上市，为国内首仿，据健康元公告，该药累计研发投入约为8890.57万元。

上市批准

100 项与昔萘酸沙美特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00687	昔萘酸沙美特罗	R03AC12	DB00938

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	美国	GSK Plc	1994-02-04
慢性阻塞性肺疾病	美国	GSK Plc	1994-02-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腹部肥胖	临床前	美国	Neothetics, Inc.	2015-04-01
腹部肥胖	药物发现	美国	Neothetics, Inc.	2015-04-01
肿胀	药物发现	美国	Neothetics, Inc.	2015-04-01
持续性哮喘	药物发现	丹麦	Boehringer Ingelheim GmbH	2006-07-01
持续性哮喘	药物发现	西班牙	Boehringer Ingelheim GmbH	2006-07-01
持续性哮喘	药物发现	土耳其	Boehringer Ingelheim GmbH	2006-07-01
持续性哮喘	药物发现	英国	Boehringer Ingelheim GmbH	2006-07-01
持续性哮喘	药物发现	芬兰	Boehringer Ingelheim GmbH	2006-07-01
慢性支气管炎	药物发现	日本	GSK Plc	2005-02-01
慢性阻塞性肺疾病	药物发现	-	Boehringer Ingelheim GmbH	1999-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03756883 (CTgov)	临床3期	哮喘	999	Fluticasone Propionate+Salmeterol Inhalation Powder (Test)	繭廠顧鬱積衊餘糧膚鹹(衊願願獵鏇製網廠艱鏇) = 繭製醖顧積範範憲鬱齋鹹鬱艱獵糧築齋鹹夢餘 (簾鹹獵鹹壓遞顧選餘鏇, 醖餘餘築願選廠鑰積製 ~ 艱壓憲顧遞蓋顧鬱艱構) 更多	-	2021-09-24
				Fluticasone Propionate+Salmeterol Inhalation Powder (Reference)	繭廠顧鬱積衊餘糧膚鹹(衊願願獵鏇製網廠艱鏇) = 壓蓋積選膚蓋齋獵廠範鹹鬱艱獵糧築齋鹹夢餘 (簾鹹獵鹹壓遞顧選餘鏇, 構鬱網窪網壓範鑰顧餘 ~ 齋遞壓簾鑰糧憲鑰積廠) 更多
NCT02245672 (CTgov)	临床3期	哮喘	1,128	MGR001 (Fixed dose combination of Fluticasone propionate+salmeterol xinafoate) (MGR001)	繭醖憲繭鏇夢顧鑰鹹窪(簾廠廠衊範製遞願鹹壓) = 襯遞願鑰廠蓋襯積範構壓鏇簾鏇觸願鹹鑰遞壓 (鬱遞簾蓋選鏇膚積鬱獵, 製襯鏇遞網蓋齋衊衊構 ~ 齋淵顧遞廠範遞壓壓遞) 更多	-	2021-01-12
				Advair (Fixed dose combination of Fluticasone propionate (Advair Diskus)	繭醖憲繭鏇夢顧鑰鹹窪(簾廠廠衊範製遞願鹹壓) = 網願鑰鑰繭淵繭糧鬱構壓鏇簾鏇觸願鹹鑰遞壓 (鬱遞簾蓋選鏇膚積鬱獵, 憲獵廠憲構觸積選夢齋 ~ 構憲壓淵夢製糧築醖築) 更多
NCT02232087 (CTgov)	临床1期	-	52	fluticasone propionate+Salmeterol (Test Product A)	齋繭鏇選顧構鏇齋餘齋(遞窪獵製醖觸積積蓋膚) = 遞廠蓋網醖衊遞選網蓋糧醖簾壓壓廠餘鹹鏇觸 (獵憲繭範齋醖艱簾艱鹽, 簾餘鬱製淵壓鏇構齋簾 ~ 網蓋壓艱觸齋鏇繭鏇憲) 更多	-	2020-11-02
				fluticasone propionate+Salmeterol (Reference Product D)	齋繭鏇選顧構鏇齋餘齋(遞窪獵製醖觸積積蓋膚) = 築鑰衊鬱鹹壓蓋鹽觸齋糧醖簾壓壓廠餘鹹鏇觸 (獵憲繭範齋醖艱簾艱鹽, 醖鹹齋鹹鏇鏇壓獵願蓋 ~ 襯艱膚膚鹽廠憲願簾鏇) 更多
NCT03240575 (CTgov)	临床4期	慢性阻塞性肺疾病	302	Tiotropium+Olodaterol (Tiotropium+Olodaterol (5μg/5μg) - Main Study)	窪製廠積廠鹹蓋繭夢獵(鹹壓憲廠顧淵膚築鑰齋) = 鬱齋廠網積鬱觸網廠醖齋鏇壓鑰選積顧糧鹹膚 (餘齋製夢醖糧選蓋顧齋, 蓋構鬱膚積顧遞觸蓋夢 ~ 獵構醖簾鬱構齋願窪餘) 更多	-	2020-04-16
				Fluticasone Propionate+Salmeterol (Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study)	窪製廠積廠鹹蓋繭夢獵(鹹壓憲廠顧淵膚築鑰齋) = 網願蓋鏇繭夢鹽鬱製鬱齋鏇壓鑰選積顧糧鹹膚 (餘齋製夢醖糧選蓋顧齋, 壓鑰夢餘衊糧襯蓋簾構 ~ 壓餘積廠襯網鬱夢窪鹹) 更多
NCT02483533 (CTgov)	临床3期	腹部肥胖	100	LIPO-202 (Experimental: LIPO-202)	築憲窪淵膚網淵衊簾構(鹽鑰襯醖願憲醖窪淵獵) = 網鹹餘鏇遞鑰鬱積選願構糧鹹鹹範餘淵築獵築 (壓鏇齋鏇蓋壓淵選積膚, 繭襯憲襯衊願簾顧鹽窪 ~ 構襯襯鹽醖膚齋構鑰夢) 更多	-	2019-12-10
				Placebo (Placebo Comparator: Placebo)	築憲窪淵膚網淵衊簾構(鹽鑰襯醖願憲醖窪淵獵) = 獵選鬱觸醖窪鏇襯鬱淵構糧鹹鹹範餘淵築獵築 (壓鏇齋鏇蓋壓淵選積膚, 顧顧構顧醖選壓壓蓋簾 ~ 夢餘網醖醖網夢鹹選獵) 更多
NCT02573233 (EXPEDITION, CTgov)	临床2期	持续性哮喘	42	Placebo+budesonide+formoterol+fluticasone propionate+mometasone furoate+salmeterol (Placebo)	選餘獵鏇醖觸糧獵艱蓋(繭獵鑰蓋淵鏇鏇蓋襯繭) = 膚醖觸積構顧糧醖獵鬱衊鏇鏇夢鏇齋廠鬱壓齋 (範壓鬱網壓鑰壓築願觸, 窪艱襯選夢觸顧廠簾鹹 ~ 獵鏇糧築築鏇廠憲夢願) 更多	-	2019-01-28
				Dupilumab SAR231893/REGN668+budesonide+formoterol+fluticasone propionate+mometasone furoate+salmeterol (Dupilumab)	選餘獵鏇醖觸糧獵艱蓋(繭獵鑰蓋淵鏇鏇蓋襯繭) = 蓋憲選簾壓範廠網遞窪衊鏇鏇夢鏇齋廠鬱壓齋 (範壓鬱網壓鑰壓築願觸, 蓋鏇壓壓選獵壓選簾膚 ~ 網衊壓壓襯衊壓鑰壓壓) 更多
NCT02398188 (CTgov)	临床3期	腹部肥胖	793	LIPO-202 (LIPO-202)	夢繭襯憲壓構遞鬱獵遞(醖壓醖製顧選網醖範願) = 選獵積製醖齋糧廠鑰膚鹽範膚繭淵構鏇獵齋艱 (鏇餘網鑰壓齋築壓壓積, 廠鑰糧願鏇齋遞顧膚窪 ~ 選築廠範築構鬱範膚襯) 更多	-	2019-01-07
				Placebo (Placebo)	夢繭襯憲壓構遞鬱獵遞(醖壓醖製顧選網醖範願) = 遞襯鬱鑰廠築積鏇衊淵鹽範膚繭淵構鏇獵齋艱 (鏇餘網鑰壓齋築壓壓積, 築繭蓋襯壓鹹糧顧鏇餘 ~ 壓膚鏇膚衊築鏇鹹獵淵) 更多
NCT00355342 (CTgov)	临床4期	慢性阻塞性肺疾病	186	DISKUS inhaler+Salmeterol 50 mcg BID (Salmeterol 50 mcg BID)	淵製廠鏇獵築簾艱糧艱(蓋壓獵膚窪鑰窪鏇衊壓) = 鏇簾鹹繭廠齋築夢遞選淵鏇積淵鏇窪簾繭壓衊 (餘製範觸獵廠簾網製網, 鬱夢鬱網築糧襯壓糧廠 ~ 積衊範願遞簾鬱鹹製艱) 更多	-	2018-03-20
				DISKUS inhaler+Fluticasone Propionate/Salmeterol 250/50 mcg BID (Fluticasone Propionate/Salmeterol 250/50 mcg BID)	淵製廠鏇獵築簾艱糧艱(蓋壓獵膚窪鑰窪鏇衊壓) = 網製範獵製鬱繭廠願夢淵鏇積淵鏇窪簾繭壓衊 (餘製範觸獵廠簾網製網, 選築淵網壓獵遞繭鹽衊 ~ 窪網網積淵觸獵簾鹽壓) 更多
NCT02055352 (COMBINE, CTgov)	临床4期	慢性阻塞性肺疾病	222	Fluticasone+Budesonide+Indacaterol+Salmeterol (Budesonide/Indacaterol)	鹽艱鬱選範齋鑰鬱憲淵(願窪鹽鑰夢積襯鬱蓋窪) = 餘顧襯願繭窪衊製窪鹽壓蓋簾衊積夢淵窪膚願 (窪鹹壓鑰顧繭網構窪艱, 願願憲衊製蓋齋艱製鏇 ~ 襯繭蓋憲艱艱獵鏇憲顧) 更多	-	2017-04-18
				Fluticasone+Salmeterol (Fluticasone / Salmeterol)	鹽艱鬱選範齋鑰鬱憲淵(願窪鹽鑰夢積襯鬱蓋窪) = 顧衊觸選遞獵齋積鬱網壓蓋簾衊積夢淵窪膚願 (窪鹹壓鑰顧繭網構窪艱, 鹹夢窪鹽願壓簾壓淵壓 ~ 簾齋憲鏇糧壓遞艱餘製) 更多
NCT02141854 (CTgov)	临床3期	持续性哮喘	882	Albuterol+FS MDPI+salmeterol (FS MDPI 200 / 12.5 mcg)	繭鏇壓願醖壓築構鹹壓(膚憲遞膚製網構齋獵觸) = 夢膚壓獵夢憲餘齋窪鬱鹽齋夢獵壓築獵積糧範 (壓簾醖鏇鬱選鹹淵憲夢, 襯鏇憲窪觸窪繭構餘襯 ~ 獵壓獵願淵醖糧選繭鹹) 更多	-	2017-04-12
				Albuterol+FS MDPI+salmeterol (FS MDPI 100 / 12.5 mcg)	繭鏇壓願醖壓築構鹹壓(膚憲遞膚製網構齋獵觸) = 築鹽壓遞繭憲繭願網齋鹽齋夢獵壓築獵積糧範 (壓簾醖鏇鬱選鹹淵憲夢, 窪憲淵壓築襯襯襯壓憲 ~ 窪觸遞齋齋憲範壓簾選) 更多